Equities research analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Trading Down 4.3 %
NASDAQ:PULM opened at $2.02 on Tuesday. The company has a market capitalization of $7.37 million, a P/E ratio of -0.84 and a beta of 0.99. The firm has a fifty day simple moving average of $2.10 and a 200-day simple moving average of $1.99. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The business had revenue of $1.55 million for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- What is a SEC Filing?
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- The How and Why of Investing in Gold Stocks
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Dividend Payout Ratio Calculator
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
